Advanced Heart Failure Therapies: Specific Considerations for Cardio-Oncology Patients

AbstractPurpose of ReviewHeart failure and cancer share common risk factors. We sought to describe outcomes of advanced heart failure therapies in the cardio-oncology population.Recent FindingsStudies specific to outcomes in patients with either active cancer or chemotherapy-induced cardiomyopathy (CCMP) are limited. Despite this, studies on highly selected cohorts have suggested similar outcomes after heart transplant in those with and without a history of cancer. Conversely, data regarding heart transplant in CCMP have shown mixed outcomes with similar or worse survival. Left ventricular assist device appears to confer similar survival in those with CCMP, but data in those with active cancer remains scarce.SummaryHeart transplant or mechanical circulatory support may achieve acceptable outcomes in the cardio-oncology patient with end-stage heart failure. Individualized patient decision-making is critical and a team-based approach is necessary. More research is needed as both cancer treatment and heart failure therapies continue to evolve.
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research